Informations

At the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO), Professor Jiwei Huang, on behalf of the research team, delivered an oral presentation reporting the latest efficacy and safety data from a multicenter, single-arm, Phase II clinical study. The trial evaluated fruquintinib in combination with serplulimab as a first-line treatment for patients…

At a recent international oncology conference, Professor Tom Powles from the Barts Cancer Centre in London presented the latest results from the RC48-G001 study. This global, multicenter Phase 2 trial evaluated disitamab vedotin (RC48) in patients with HER2-expressing, previously treated advanced urothelial carcinoma (UC). As a HER2-targeted antibody-drug conjugate (ADC) utilizing a monomethyl auristatin E…

At a recent academic session, Professor Taigo Kato from the Osaka University Graduate School of Medicine presented the preliminary results of the MONSTAR-SCREEN-3 study. The study investigates the clinical utility of an ultra-sensitive whole-genome sequencing (WGS)-based circulating tumor DNA (ctDNA) assay for the detection of molecular residual disease (MRD) in patients with resectable renal cell…

At a recent international medical congress, Dr. Steffen Rausch from the University Hospital Tübingen presented the latest analysis of pathological outcomes and disease-free survival (DFS) from the KEYNOTE-905 study. This randomized, open-label Phase III trial evaluates the efficacy and safety of perioperative enfortumab vedotin (EV) combined with pembrolizumab in patients with muscle-invasive bladder cancer (MIBC)…

At a recent international academic symposium, Dr. Sophie Merrick from the Medical Research Council Clinical Trials Unit at University College London (UCL) reported the Patient-Reported Outcome (PRO) data from the RAMPART trial. The study aimed to evaluate the dynamic impact of adjuvant durvalumab plus tremelimumab versus active monitoring on the quality of life (QoL) of…

For patients with advanced renal cell carcinoma (RCC) who have progressed after anti-PD-(L)1 therapy, a consensus standard of care is currently lacking. Belzutifan, a first-in-class HIF-2α inhibitor, combined with the VEGFR-TKI lenvatinib, has emerged as a promising therapeutic strategy. At a recent academic conference, Professor Robert J. Motzer from Memorial Sloan Kettering Cancer Center (MSKCC)…

At the recent genitourinary oncology symposium, Dr. Pooja Ghatalia from Fox Chase Cancer Center presented the primary clinical outcomes of the RETAIN 2 trial. She also provided an integrated analysis of the RETAIN 1 and RETAIN 2 trials, focusing on the role of circulating tumor DNA (ctDNA) in guiding response-adapted bladder preservation for patients with…

At the recent ASCO Annual Meeting, Professor Michiel S. van der Heijden from the Netherlands Cancer Institute (NKI) presented the latest biomarker analysis from the Phase III NIAGARA trial. The study investigated the dynamics of urinary tumor DNA (utDNA) and circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) receiving perioperative durvalumab in…